A one-page document describing RV144, the first AIDS vaccine trial to show protection against HIV in humans, and plans to further this research.
AIDS Vaccine Science for Busy Advocates – RV144: Building on a breakthrough
HIV Vaccines: Key messages
This is a three-page document providing main points surrounding vaccine research. For a shorter one-page version of this, click here.
The Change We Need to End AIDS in Uganda: A civil society analysis of the state of Uganda’s AIDS response
This document, developed by a coalition of civil society groups co-led by AVAC Advocacy Fellows Alice Kayong-Mutebi, Richard Hasunira and Sylvia Nakasi, identifies failures in the Ugandan AIDS response and a 10-point plan to end the country’s epidemic.
Letter to Ambassador Goosby on PEPFAR and the national response to HIV in Uganda in 2012-13
This letter, written by a coalition of civil society groups co-led by AVAC Advocacy Fellows Alice Kayong-Mutebi, Richard Hasunira and Sylvia Nakasi, summarizes concerns and demands related to the US PEPFAR program’s 2012 Country Operating Plan. A country operating plan dictates the scope, funding levels and targets of PEPFAR programming on an annual basis.
Good Participatory Practice: Guidelines for biomedical HIV prevention trials second edition (Thai)
The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials.
This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.
Good Participatory Practice: Guidelines for biomedical HIV prevention trials second edition (Russian)
The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials.
This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.
Good Participatory Practice: Guidelines for biomedical HIV prevention trials second edition (Portuguese)
The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials.
This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.
Letter to Ambassador Goosby from Kenyan Civil Society
This letter on behalf of civil society organizations working in HIV and AIDS in Kenya offers recommendations for PEPFAR’s Kenya Country Operational Plan (COP) in 2013. The letter includes calls for increased investment in HIV treatment options and enhanced participation of CSO-selected civil society groups in every stage of the COP drafting process.
Community Stakeholder Checklist
The Community Stakeholder Checklist is a set of questions that can be used by community stakeholders to evaluate a research team’s compliance with the Good Participatory Practice guidelines. The checklist can be used as a starting point for dialogue with a research team, a way to share experiences with other stakeholders or as an assessment tool.
Capitalizing on Scientific Progress: Investment in HIV Prevention R&D in 2010
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2011 report describes the funding environment in the wake of a number of the findings of efficacy in the RV144, CAPRISA, iPrEx and HPTN 025 trials and calls for sustained funding to build on these results.